

EDSS: Percentage Change from Part 1 baseline to each scheduled efficacy visit in Part 2  
 Subgroup Analysis: Confirmed Progression of disability  
 ITT population

Confirmed Progressors

	Placebo to Natalizumab 300 mg	Natalizumab 300 mg	p-value (a)
Percentage change from Baseline to Week 156			
n	162	141	
Mean	7.23	7.30	0.9121
SD	13.513	15.728	

(a) p-value for comparison between the active and placebo groups at Week 156 is based on ANCOVA model, adjusted for baseline EDSS (<=5.5 or >=6).

EDSS: Percentage Change from Part 1 baseline to each scheduled efficacy visit in Part 2  
 Subgroup Analysis: Confirmed Progression of disability  
 ITT population  
 Page 12 of 12  
 Non Progressors

	Placebo to Natalizumab 300 mg	Natalizumab 300 mg	p-value (a)
Percentage change from Baseline to Week 156			
n	98	134	
Mean	-6.47	-4.29	0.2594
SD	13.951	15.266	

(a) p-value for comparison between the active and placebo groups at Week 156 is based on ANCOVA model, adjusted for baseline EDSS ( $\leq 5.5$  or  $\geq 6$ ).